Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 Evolution of MMV Portfolio. 2 MMV Portfolio May 2000-2001 Dihydroorotate dehydrogenase inhibition (DHOD) Dihydrofolate reductase (DHFR) Falcipains Lactate.

Published byClaire Snow Modified over 7 years ago

Similar presentations

Presentation on theme: "1 Evolution of MMV Portfolio. 2 MMV Portfolio May 2000-2001 Dihydroorotate dehydrogenase inhibition (DHOD) Dihydrofolate reductase (DHFR) Falcipains Lactate."— Presentation transcript:

1 1 Evolution of MMV Portfolio

2 2 MMV Portfolio May 2000-2001 Dihydroorotate dehydrogenase inhibition (DHOD) Dihydrofolate reductase (DHFR) Falcipains Lactate dehydrogenase project (LDH) ExploratoryDiscovery PreclinicalClinical Development LeadLeadTransitionPhase IPhase IIPhase III IdentificationOptimization Synthetic peroxide (OZ) Haem Polymerization

3 3 MMV Portfolio May 2001-2002 DHOD DHFR LDH ExploratoryDiscovery PreclinicalClinical Development LeadLeadTransitionPhase IPhase IIPhase III IdentificationOptimization Falcipains Synthetic peroxide (OZ) Isoquine (4- aminoquinoline) Intravenous Artesunate 3rd Generation Antifolate Pyronaridine Artesunate LapDap™ Artesunate Haem Pol Artemisone (semi-synthetic endoperoxide) Pf-PFT Fatty acid biosynthesis (FAS II)

4 4 MMV Portfolio May 2001-2002 DHFR ExploratoryDiscovery PreclinicalClinical Development LeadLeadTransitionPhase IPhase IIPhase III IdentificationOptimization Falcipains Synthetic peroxide (OZ) Isoquine Intravenous Artesunate 3rd Generation Antifolate Pyronaridine Artesunate LapDap™ Artesunate Artemisone Pf-PFT FAS II

5 5 MMV Portfolio Dec. 2003 DHFR ExploratoryDiscovery PreclinicalClinical Development LeadLeadTransitionPhase IPhase IIPhase III IdentificationOptimization Synthetic peroxide (OZ) Isoquine IV Artesunate 3 rd Generation Antifolate Pyronaridine Artesunate LapDap™ Artesunate Artemisone FAS II Pf-PFT Falcipains Pediatric Coartem ® GAPDH 4(1H)- Pyridones New dicationic molecules DB289 Fab I PDF 8-amino quinoline Manzamine A DHA Piperaquine Novel Tetracyclines

6 6 DHFR ExploratoryDiscovery PreclinicalClinical Development LeadLeadTransitionPhase IPhase IIPhase III IdentificationOptimization Synthetic peroxide (OZ) Isoquine Intravenous Artesunate Pyronaridine Artesunate LapDap™ Artesunate Artemisone FAS II Pf-PFT Falcipains Pediatric Coartem ® GAPDH 4(1H)- Pyridones New dicationic molecules DB289 PDF Novel Tetracycline Manzamine Alkaloids IV Artesunate MMV Portfolio May 2004 8-amino quinolines Fab I DHA Piperaquine

7 7 MMV Portfolio Jan. 2005 DHFR ExploratoryDiscovery PreclinicalClinical Development LeadLeadTransitionPhase IPhase IIPhase III IdentificationOptimization Synthetic peroxide (OZ) PO&IV Isoquine ) Pyronaridine artesunate LapDap™ Artesunate Pf-PFT Falcipains Pediatric Coartem ® 4(1H)- Pyridones New dicationic molecules DB289 Fab I DHA Piperaquine 8-amino quinolines Back Up Pyridones 2nd Generation (OZ) Artemifone

8 8 Peptide deformylase inhibitor (PDF) MMV Portfolio Jan. 2005 DHFR ExploratoryDiscovery PreclinicalClinical Development LeadLeadTransitionPhase IPhase IIPhase III IdentificationOptimization Synthetic peroxide (OZ) PO&IV Isoquine Pyronaridine artesunate LapDap™ Artesunate Pf-PFT Falcipains Pediatric Coartem ® 4(1H)- Pyridones New dicationic molecules DB289 Fab I DHA Piperaquine 8-amino quinolines 8-amino quinolines Back Up Pyridones 2 nd Generation (OZ) Artemifone

9 9 Structural Component 2000-Date DHFR ExploratoryDiscovery PreclinicalClinical Development LeadLeadTransitionPhase IPhase IIPhase III IdentificationOptimization Chlorproguanil- Dapsone (LapDap™) Artesunate FAS II Pf-PFT Falcipains Fab I PDF GAPDH DHODH LDH

10 10 4 th Call for Proposals 81 new proposals 10 Projects short-listed in Nov.`04 5 projects recommended for funding by ESAC this week MMV to decide on funding soon

11 11 MMV Portfolio March 2005 DHFR ExploratoryDiscovery PreclinicalClinical Development LeadLeadTransitionPhase IPhase IIPhase III IdentificationOptimization Synthetic peroxide (OZ) PO&IV Isoquine ) Pyronaridine Artesunate LapDap™ Artesunate Pf-PFT Falcipains Pediatric Coartem ® 4(1H)- Pyridones New dicationic molecules DB289 Fab I DHA Piperaquine 8-amino quinolines Back Up Pyridones 2nd Generation (OZ) Artemifone

12 12 Project Selection Round 1Round 2Round 3 Europe363437 Co-investigators87 Institutions68 North America413539 Co-investigators59 Institutions47 Developing Countries231530 Co-investigators64 Institutions56 Total10084106 Countries262123 Institutions947790

13 13 The Win/Win Proposition Joint R&D MMV Input $$$ Background IPR Link to RBM Expertise Pharma Input Chemistry IPR* Toxicology Management Know How Assets in Kind Technology Liability for Development Risk MMV Gets Rights in DEC IPR in ‘Field’ Drug Supply Return on non DEC Sales Pharma Gets Rights in non DEC IPR outside ‘Field’ PR Benefit HR Benefit Public Private

14 14 Future Challenges for MMV Funding to support large number of Clinical Studies Shortage of GCP clinical sites for trials Development & Registration of combination therapies Delivery strategy for effective use and health impact

15 15 MMV a small team, but …. 0 50 100 150 200 250 300 350 Year Scientists Engaged 200020012002200420052003

16 16 Proposed profiles of new drugs - for uncomplicated malaria Efficacy against drug resistant strains Cure within three days Safe in pregnancy Appropriate formulations and packaging Low cost of goods Further profiles Intermittent treatment in pregnancy & early infancy P. vivax malaria Severe malaria Prophylaxis Single dose cure!!

17 17 Drug Discovery Process Nwaka & Ridley 2003

Download ppt "1 Evolution of MMV Portfolio. 2 MMV Portfolio May 2000-2001 Dihydroorotate dehydrogenase inhibition (DHOD) Dihydrofolate reductase (DHFR) Falcipains Lactate."

Similar presentations

Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July 2 2003 Ties Boerma HIV Department Surveillance,

Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July Ties Boerma HIV Department Surveillance,
Malaria treatment (Current WHO recommendations & guidelines)

Malaria treatment (Current WHO recommendations & guidelines)
KINGDOM OF CAMBODIA Ministry of Health National Center for Parasitology, Entomology and Malaria Control CNM.

KINGDOM OF CAMBODIA Ministry of Health National Center for Parasitology, Entomology and Malaria Control CNM.
Malaria treatment. Dr abdulrahman al shaikh.. Introduction. 1-2.7 million patients died because of malaria every year. Most deaths due to Plasmodium Falciparum.

Malaria treatment. Dr abdulrahman al shaikh.. Introduction million patients died because of malaria every year. Most deaths due to Plasmodium Falciparum.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
World Health Organization

World Health Organization
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.

Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Choice of antimalarial drugs Malaria Medicines & Supplies Services RBM Partnership Secretariat.

Choice of antimalarial drugs Malaria Medicines & Supplies Services RBM Partnership Secretariat.
1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.

1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.

Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
Antimalarial agents Pawitra Pulbutr M.Sc. In Pharm (Pharmacology)

Antimalarial agents Pawitra Pulbutr M.Sc. In Pharm (Pharmacology)
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center 1-13-04.

INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
1 Global New Employee Orientation Workshop Welcome.

1 Global New Employee Orientation Workshop Welcome.
Malaria & the Multinationals: Public Private Partnerships APPMG All-Party Parliamentary Malaria Group BEAD Business Exchange on AIDS & Infectious Diseases.

Malaria & the Multinationals: Public Private Partnerships APPMG All-Party Parliamentary Malaria Group BEAD Business Exchange on AIDS & Infectious Diseases.
Effectiveness and risk with LapDap A classic dilemma Personal views: I Ralph Edwards.

Effectiveness and risk with LapDap A classic dilemma Personal views: I Ralph Edwards.
1 Towards the future: medicines and the elimination of malaria Defeating Malaria Together Timothy N.C. Wells PhD ScD Chief Scientific Officer MMV.

1 Towards the future: medicines and the elimination of malaria Defeating Malaria Together Timothy N.C. Wells PhD ScD Chief Scientific Officer MMV.
PMTCT at Different Levels of Care: The Uganda Experience Dr. Saul Onyango National PMTCT Coordinator Ministry of Health 1 1.

PMTCT at Different Levels of Care: The Uganda Experience Dr. Saul Onyango National PMTCT Coordinator Ministry of Health 1 1.
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.

Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Dr Stewart Hay, CEO | www.therapeuticinnovation.com.au | (03) 9670 7018www.therapeuticinnovation.com.au.

Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.

Similar presentations

Ads by Google